Related Experiment Video
Updated: Jul 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Benzyl amide-ketoacid inhibitors of HIV-integrase
Michael A Walker1, Timothy Johnson, B Narasimhulu Naidu
1Department of Medicinal Chemistry, Research and Development, Bristol-Myers Squibb, The Richard L Gelb Center for Pharmaceutical Research and Development, Wallingford, CT 06492, USA. michael.a.walker@bms.com
Abstract:
Integrase is one of three enzymes expressed by HIV and represents a validated target for therapy. Previous reports have demonstrated that the diketoacid-based chemotype is a useful starting point for the design of inhibitors of this enzyme. In this study, one of the ketone groups is replaced by a benzylamide resulting in a new potent chemotype. A preliminary SAR study is carried out to investigate the substitution requirements on the phenyl ring and methylene group of the benzylamide.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Inhibitors Of Virion Release
Retrovirus Life Cycles

